A tissue-specific negative result is narrower than proof that diabetes never changes drug exposure.
Duodenal biopsies from twenty patients with type 2 diabetes and sixteen without it were examined for gene expression and probe-drug metabolism. Midazolam was used for CYP3A activity. The tested intestinal enzyme and transporter measures did not differ substantially between groups, despite higher inflammatory-marker levels in the diabetes group.
The study assessed biopsy preparations rather than administered-dose pharmacokinetics. Small groups limit precision, and the liver or other intestinal regions may behave differently. No detected difference is not proof that every relevant metabolic effect is absent.
For a benzodiazepine exposure opinion, avoid attributing altered clearance to diabetes solely from the diagnosis. Consider the organ, pathway, disease control and actual concentration evidence. The paper cautions against turning a whole-body clinical observation into an assumed duodenal mechanism.
Source reviewed: A Pilot Study towards the Impact of Type 2 Diabetes on the Expression and Activities of Drug Metabol (PMC6651059). Forensic applications above are interpretive analysis of the supplied publication.
Related reading: Basmisanil’s Rat Memory Effects and Human Target Engagement Were Different Evidence Streams.